Halozyme Therapeutics Inc (HALO)
49.00
+3.30
(+7.22%)
USD |
NASDAQ |
Nov 22, 16:00
48.52
-0.48
(-0.98%)
After-Hours: 20:00
Halozyme Therapeutics Revenue (TTM): 947.36M for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 947.36M |
| June 30, 2024 | 873.30M |
| March 31, 2024 | 862.99M |
| December 31, 2023 | 829.25M |
| September 30, 2023 | 780.71M |
| June 30, 2023 | 773.65M |
| March 31, 2023 | 704.98M |
| December 31, 2022 | 660.12M |
| September 30, 2022 | 580.62M |
| June 30, 2022 | 487.48M |
| March 31, 2022 | 471.57M |
| December 31, 2021 | 443.31M |
| September 30, 2021 | 463.01M |
| June 30, 2021 | 412.50M |
| March 31, 2021 | 331.26M |
| December 31, 2020 | 267.59M |
| September 30, 2020 | 199.56M |
| June 30, 2020 | 180.47M |
| March 31, 2020 | 164.40M |
| December 31, 2019 | 195.99M |
| September 30, 2019 | 202.56M |
| June 30, 2019 | 181.88M |
| March 31, 2019 | 177.94M |
| December 31, 2018 | 151.86M |
| September 30, 2018 | 281.19M |
| Date | Value |
|---|---|
| June 30, 2018 | 319.37M |
| March 31, 2018 | 317.92M |
| December 31, 2017 | 316.61M |
| September 30, 2017 | 166.05M |
| June 30, 2017 | 134.17M |
| March 31, 2017 | 133.76M |
| December 31, 2016 | 146.69M |
| September 30, 2016 | 159.92M |
| June 30, 2016 | 148.84M |
| March 31, 2016 | 158.89M |
| December 31, 2015 | 135.06M |
| September 30, 2015 | 113.21M |
| June 30, 2015 | 107.03M |
| March 31, 2015 | 82.03M |
| December 31, 2014 | 75.33M |
| September 30, 2014 | 57.46M |
| June 30, 2014 | 58.86M |
| March 31, 2014 | 54.93M |
| December 31, 2013 | 54.80M |
| September 30, 2013 | 64.09M |
| June 30, 2013 | 53.42M |
| March 31, 2013 | 46.72M |
| December 31, 2012 | 42.32M |
| September 30, 2012 | 22.94M |
| June 30, 2012 | 40.55M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
164.40M
Minimum
Mar 2020
947.36M
Maximum
Sep 2024
531.51M
Average
479.52M
Median
Revenue (TTM) Benchmarks
| Lexicon Pharmaceuticals Inc | 5.229M |
| Novavax Inc | 847.25M |
| Kura Oncology Inc | -- |
| TransMedics Group Inc | 401.09M |
| Pulmonx Corp | 79.30M |